Vaccine

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimensNEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc.…

5 months ago

Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025

Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA…

5 months ago

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

HUNTSVILLE, AL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing…

5 months ago

Clinical Research in LATAM: From a Standalone Site to a Regional Network, Upcoming Webinar Hosted by Xtalks

This free webinar teaches you how to scale a clinical research site into a regional network without sacrificing quality or…

5 months ago

Xtalks Announces its Life Science Webinar Calendar for September 2025

Upcoming free, educational webinars from Xtalks will feature topics on biomarkers, biotech, cell and gene therapy, clinical trials, drug discovery &…

5 months ago

Branded Legacy, Inc. Expands Capabilities with Acquisition of State-of-the-Art GMP Facility in Vancouver

Empowering BioLegacy to Lead Innovation in Combating the Opioid Epidemic Through Advanced Manufacturing and ResearchVANCOUVER, British Columbia, Sept. 04, 2025…

5 months ago

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf…

5 months ago

Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism

CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its…

5 months ago

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention…

5 months ago

Contract Research Organization (CRO) Services Market worth $125.95 billion in 2030 with 8.3% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Sept. 1, 2025 /PRNewswire/ -- The global Contract Research Organization Services Market, valued at US$79.10 billion in…

5 months ago